Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label trial of TMC125 (etravirine) in antiretroviral-experienced HIV-1 infected children and adolescents
2007-007086-21Phase 2Completed
- Sponsor
- Tibotec
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etravirine in Human immunodeficiency virus infection type 1, sponsored by Tibotec. Primary endpoints: Primary safety and tolerability (24 weeks), Primary safety and tolerability (48 weeks) and 1 more. Started May 2008; status: completed.
02
Drugs
etravirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2007-007086-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007086-21.